JP7756072B2 - Ｔ細胞調節ポリペプチド及びその使用方法 - Google Patents

Ｔ細胞調節ポリペプチド及びその使用方法

Info

Publication number
JP7756072B2
JP7756072B2 JP2022506595A JP2022506595A JP7756072B2 JP 7756072 B2 JP7756072 B2 JP 7756072B2 JP 2022506595 A JP2022506595 A JP 2022506595A JP 2022506595 A JP2022506595 A JP 2022506595A JP 7756072 B2 JP7756072 B2 JP 7756072B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
tmp
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548472A5 (https=
JPWO2021055594A5 (https=
JP2022548472A (ja
Inventor
ザ サード ロナルド ディー． セイデル
ロドルフォ ジェイ． チャパーロ
ジョン エフ． ロス
サソ チェメルスキ
Original Assignee
キュー バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ， インコーポレイテッド filed Critical キュー バイオファーマ， インコーポレイテッド
Publication of JP2022548472A publication Critical patent/JP2022548472A/ja
Publication of JP2022548472A5 publication Critical patent/JP2022548472A5/ja
Publication of JPWO2021055594A5 publication Critical patent/JPWO2021055594A5/ja
Application granted granted Critical
Publication of JP7756072B2 publication Critical patent/JP7756072B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022506595A 2019-09-20 2020-09-17 Ｔ細胞調節ポリペプチド及びその使用方法 Active JP7756072B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962903441P 2019-09-20 2019-09-20
US62/903,441 2019-09-20
US202062990693P 2020-03-17 2020-03-17
US62/990,693 2020-03-17
US202063048561P 2020-07-06 2020-07-06
US63/048,561 2020-07-06
PCT/US2020/051255 WO2021055594A1 (en) 2019-09-20 2020-09-17 T-cell modulatory polypeptides and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2022548472A JP2022548472A (ja) 2022-11-21
JP2022548472A5 JP2022548472A5 (https=) 2023-09-25
JPWO2021055594A5 JPWO2021055594A5 (https=) 2023-09-25
JP7756072B2 true JP7756072B2 (ja) 2025-10-17

Family

ID=74884186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506595A Active JP7756072B2 (ja) 2019-09-20 2020-09-17 Ｔ細胞調節ポリペプチド及びその使用方法

Country Status (11)

Country Link
US (2) US20220143063A1 (https=)
EP (1) EP4030897A4 (https=)
JP (1) JP7756072B2 (https=)
KR (1) KR20220066075A (https=)
CN (1) CN114423284A (https=)
AU (1) AU2020348373A1 (https=)
CA (1) CA3146591A1 (https=)
IL (1) IL290635A (https=)
MX (1) MX2022003367A (https=)
TW (1) TW202126683A (https=)
WO (1) WO2021055594A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
US12453774B2 (en) * 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US12275766B2 (en) * 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
JP2024512470A (ja) * 2021-03-19 2024-03-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節ポリペプチド及びその使用方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN119095882A (zh) * 2022-04-07 2024-12-06 Cue生物制药股份有限公司 免疫细胞结合多肽
CN115820736B (zh) * 2022-12-08 2024-05-10 西南大学 家蚕丝胶蛋白Ser4在提高蚕丝性能中的应用及其方法
WO2024264007A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2024264004A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519491A (ja) 2014-06-18 2017-07-20 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ｓｙｎＴａｃポリペプチド及びその使用
JP2018513135A (ja) 2015-03-23 2018-05-24 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
JP2019511458A (ja) 2016-01-27 2019-04-25 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 組み換えＩｇＧ Ｆｃ多量体
WO2021230247A1 (ja) 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017225787B2 (en) * 2016-03-03 2021-09-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3019005A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) * 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) * 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519491A (ja) 2014-06-18 2017-07-20 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ｓｙｎＴａｃポリペプチド及びその使用
JP2018513135A (ja) 2015-03-23 2018-05-24 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
JP2019511458A (ja) 2016-01-27 2019-04-25 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 組み換えＩｇＧ Ｆｃ多量体
WO2021230247A1 (ja) 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物

Also Published As

Publication number Publication date
IL290635A (en) 2022-04-01
CN114423284A (zh) 2022-04-29
TW202126683A (zh) 2021-07-16
US20220143063A1 (en) 2022-05-12
US20250120996A1 (en) 2025-04-17
CA3146591A1 (en) 2021-03-25
EP4030897A4 (en) 2023-10-18
KR20220066075A (ko) 2022-05-23
WO2021055594A1 (en) 2021-03-25
MX2022003367A (es) 2022-04-11
AU2020348373A1 (en) 2022-02-24
JP2022548472A (ja) 2022-11-21
EP4030897A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
JP7756072B2 (ja) Ｔ細胞調節ポリペプチド及びその使用方法
TWI856047B (zh) 多聚體ｔ細胞調節多肽及其使用方法
US20240067700A1 (en) T-cell modulatory polypeptides and methods of use thereof
JP7743428B2 (ja) 多量体ｔ細胞調節性ポリペプチド及びその使用方法
TW202112804A (zh) 多特異性蛋白質
CN113286621A (zh) 多聚体t细胞调节多肽及其使用方法
US20230414777A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
CN114423497A (zh) 修饰的细胞毒性t细胞及其使用方法
TW202039541A (zh) 多聚體ｔ細胞調節多肽及其使用方法
JP2023541996A (ja) ＳＩＲＰ１αキメラタンパク質の臨床投与
US20260109958A1 (en) T-Cell Modulatory Polypeptides and Methods of Use Thereof
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40060108A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40089384A (zh) 多聚体t细胞调节多肽及其使用方法
EA049816B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
HK40060108B (zh) 多聚体t细胞调节多肽及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251006

R150 Certificate of patent or registration of utility model

Ref document number: 7756072

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150